Cargando…
Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine
We analyzed the genomic and phosphoproteomic profiles of breast cancer tissue obtained from six patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who had highly durable (≥5 years) and, in some cases, ongoing clinical responses with capecitabine. Formalin-fixed, pa...
Autores principales: | Levin, Maren K, Wang, Kai, Yelensky, Roman, Cao, Ying, Ramos, Corinne, Hoke, Nicholas, Pippen, John, Blum, Joanne L, Brooks, Barry, Palmer, Gary, Palma, Norma, Balasubramanian, Sohail, Ross, Jeffrey S, O’Shaughnessy, Joyce |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559040/ https://www.ncbi.nlm.nih.gov/pubmed/25871911 http://dx.doi.org/10.1002/cam4.464 |
Ejemplares similares
-
Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer
por: Holmes, Frankie Ann, et al.
Publicado: (2018) -
Constraint of gene expression by the chromatin remodelling protein CHD4 facilitates lineage specification
por: O'Shaughnessy-Kirwan, Aoife, et al.
Publicado: (2015) -
A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007) -
A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008) -
Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)